Short Interest in Applied DNA Sciences, Inc. (NASDAQ:APDN) Decreases By 5.1%

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 5,030,000 shares, a drop of 5.1% from the December 15th total of 5,300,000 shares. Based on an average daily volume of 6,020,000 shares, the short-interest ratio is currently 0.8 days.

Institutional Investors Weigh In On Applied DNA Sciences

A hedge fund recently bought a new stake in Applied DNA Sciences stock. Jane Street Group LLC bought a new stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 73,396 shares of the technology company’s stock, valued at approximately $48,000. Jane Street Group LLC owned 0.24% of Applied DNA Sciences as of its most recent filing with the Securities & Exchange Commission. 22.22% of the stock is owned by hedge funds and other institutional investors.

Applied DNA Sciences Stock Up 0.7 %

Shares of APDN opened at $0.19 on Friday. The stock has a market cap of $10.01 million, a P/E ratio of -0.03 and a beta of 0.40. The business’s 50 day moving average price is $0.19 and its 200-day moving average price is $0.55. Applied DNA Sciences has a 52 week low of $0.12 and a 52 week high of $14.40.

Applied DNA Sciences (NASDAQ:APDN) last released its earnings results on Tuesday, December 17th. The technology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.01. Applied DNA Sciences had a negative return on equity of 111.18% and a negative net margin of 203.76%. On average, equities analysts anticipate that Applied DNA Sciences will post -0.87 EPS for the current year.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.